Anderson Kristin, Jacobson Judith S, Heitjan Daniel F, Zivin Joshua Graff, Hershman Dawn, Neugut Alfred I, Grann Victor R
Herbert Irving Comprehensive Cancer Center, College of Physicians and Surgeons, Joseph L. Mailman School of Public Health, Columbia University, and New York Presbyterian Hospital, New York, New York 10032, USA.
Ann Intern Med. 2006 Mar 21;144(6):397-406. doi: 10.7326/0003-4819-144-6-200603210-00006.
For BRCA1 or BRCA2 mutation carriers, decision analysis indicates that prophylactic surgery or chemoprevention leads to better survival than surveillance alone.
To evaluate the cost-effectiveness of the preventive strategies that are available to unaffected women carrying a single BRCA1 or BRCA2 mutation with high cancer penetrance.
Markov modeling with Monte Carlo simulations and probabilistic sensitivity analyses.
Breast and ovarian cancer incidence and mortality rates, preference ratings, and costs derived from the literature; the Surveillance, Epidemiology, and End Results (SEER) Program; and the Health Care Financing Administration (now the Centers for Medicare & Medicaid Services).
Unaffected carriers of a single BRCA1 or BRCA2 mutation 35 to 50 years of age.
Lifetime.
Health policy, societal.
Tamoxifen, oral contraceptives, bilateral salpingo-oophorectomy, mastectomy, both surgeries, or surveillance.
Cost-effectiveness.
RESULTS OF BASE-CASE ANALYSIS: For mutation carriers 35 years of age, both surgeries (prophylactic bilateral mastectomy and oophorectomy) had an incremental cost-effectiveness ratio over oophorectomy alone of 2352 dollars per life-year for BRCA1 and 100 dollars per life-year for BRCA2. With quality adjustment, oophorectomy dominated all other strategies for BRCA1 and had an incremental cost-effectiveness ratio of 2281 dollars per life-year for BRCA2.
Older age at intervention increased the cost-effectiveness of prophylactic mastectomy for BRCA1 mutation carriers to 73,755 dollars per life-year. Varying the penetrance, mortality rates, costs, discount rates, and preferences had minimal effects on outcomes.
Results are dependent on the accuracy of model assumptions.
On the basis of this model, the most cost-effective strategies for BRCA mutation carriers, with and without quality adjustment, were oophorectomy alone and oophorectomy and mastectomy, respectively.
对于携带BRCA1或BRCA2基因突变的人,决策分析表明预防性手术或化学预防比单纯监测能带来更好的生存率。
评估对于携带高癌症外显率的单个BRCA1或BRCA2基因突变的未患病女性可用的预防策略的成本效益。
采用蒙特卡罗模拟和概率敏感性分析的马尔可夫模型。
来自文献、监测、流行病学和最终结果(SEER)计划以及医疗保健财务管理局(现为医疗保险和医疗补助服务中心)的乳腺癌和卵巢癌发病率及死亡率、偏好评分和成本。
年龄在35至50岁之间的单个BRCA1或BRCA2基因突变的未患病携带者。
终生。
卫生政策、社会视角。
他莫昔芬、口服避孕药、双侧输卵管卵巢切除术、乳房切除术、两种手术或监测。
成本效益。
对于35岁的基因突变携带者,两种手术(预防性双侧乳房切除术和卵巢切除术)相对于单纯卵巢切除术的增量成本效益比,BRCA1为每生命年2352美元,BRCA2为每生命年100美元。经过质量调整后,卵巢切除术在BRCA1方面优于所有其他策略,在BRCA2方面的增量成本效益比为每生命年2281美元。
干预时年龄较大使BRCA1基因突变携带者预防性乳房切除术的成本效益提高到每生命年73,755美元。改变外显率、死亡率、成本、贴现率和偏好对结果的影响最小。
结果取决于模型假设的准确性。
基于该模型,对于BRCA基因突变携带者,无论是否进行质量调整,最具成本效益的策略分别是单纯卵巢切除术和卵巢切除术加乳房切除术。